1 / 9

Technology Commercialization- BA468X

Technology Commercialization- BA468X. Financing Your Venture. Funding your enterprise. The big question- should you…. Grow organically from generated revenues OR Seek external funding to “jump start” the business (investors or loans)

kennan
Télécharger la présentation

Technology Commercialization- BA468X

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Technology Commercialization- BA468X Financing Your Venture

  2. Funding your enterprise The big question- should you…. • Grow organically from generated revenues OR • Seek external funding to “jump start” the business (investors or loans) Often it will be both! The timing, amounts, and sources of external funding that you seek is a critical aspect of your business plan

  3. Organic growth- “pay as you grow” Positives: • Allows you to retain management control and a greater proportion of financial gains • Can be lower risk- learn the markets as you go Negatives: • Growth rate of company will likely be lower due to constraints on funding for expansion • You may miss the optimal timing of your product into the market

  4. External Funding Positives: • Faster market entry when timing is important • Investors can provide knowledge, access to markets and other sources of money • There are many creative options available which you can tailor to your need Negatives: • Loss of control. VC’s will usually want a major voice in management decisions • Dilution of your financial stake in the company • Investors will expect a tangible result from their investment. “Just trust us” doesn’t work…

  5. Ongoing Growth “Private Equity” R&D Gov’t, Industry - discovery Formation Angel Institutional Public Markets • The “3 F’s” (friends, family, & fools) • - “just the basics” • Venture Capital funds • - Home run mentality • - Significant investment $$; governance and oversight • - 2003: 915 funds, $18.2 billon invested, 2,700 deals • Angel Investors • - “early and often” • - Individuals, unorganized, limited follow-on • - 2003: $18.1 billion invested, 42,000 deals Don’t overlook non-equity capital - Grants (SBIR, STTR), foundations, other? - Customer NRE - Strategic relationships (access, credibility, risk reduction / loss of freedom, …) Capital Sources for Formation and Growth

  6. Sources of Non-equity Capital: SBIR and STTR • The Small Business Innovative Research Grants (SBIR) and Small Business Technology Transfer (STTR) can be good sources of start up funds • SBIR created in 1982 and renewed at least until 2008 • Requires 2.5% of all “extra-mural” research funds must be set aside for small business development ($2B in 2005) • Many government agencies participate: DOD, NIH, NASA, DOE, NSF, DOC, DoAg, EPA, DOE, DOT, HSArpa. Each agency has structured their program differently • There are some differences in SBIR and STTR with respect to required partnerships and percentage of total funds allocated • This a grant, NOT a loan. The small business is not required to repay. Also, the company can allocate up to 7% of the grant to profit.

  7. SBIR/STTR Funding • Structured around a 3 phase process • Phase 1- feasibility ($50K-$100K, 6 mo) • Phase 2- prototype ($500K-$750K, 2 yr) • Phase 3- commercialization (not funded by government directly) • Can be either a grant or contract • Grant- no expectation of a product that funding agency will buy • Contract- expectation that in Phase 3 that agency will be a customer

  8. SBIR/STTR Funding • Success rates vary among agencies • NIH: Funds 1 out of 3 proposals • NSF: Funds 1 out of 13 proposals • 41% of SBIR awardees are 2-9 employees • 33% of SBIR awardees are new • More information is available at the website: http://www.sbirworld.com, and is also posted on our class website accessible through the syllabus

  9. Senate Bill 853 • The State of Oregon passed a bill in 2005 for the purpose of “facilitating the commercialization of university R&D” • This fund is to provide • Capital for university entrepreneurial programs • Opportunities for students to gain experience in applying research to commercial activities • Proof-of-concept funding • Entrepreneurial opportunities for those wishing to convert research into commercial enterprises • It will be funded by credits applied to state income taxes on a voluntary basis- implementation details are still being worked out • OSU, UO, and OHSU have expressed interest in participating

More Related